Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice

J M Arbeit, P M Howley, D Hanahan, J M Arbeit, P M Howley, D Hanahan

Abstract

High-risk human papillomaviruses (HPVs), including type 16, have been identified as factors in cervical carcinogenesis. However, the presence and expression of the virus per se appear to be insufficient for carcinogenesis. Rather, cofactors most likely are necessary in addition to viral gene expression to initiate neoplasia. One candidate cofactor is prolonged exposure to sex hormones. To examine the possible effects of estrogen on HPV-associated neoplasia, we treated transgenic mice expressing the oncogenes of HPV16 under control of the human keratin-14 promoter (K14-HPV16 transgenic mice) and nontransgenic control mice with slow release pellets of 17beta-estradiol. Squamous carcinomas developed in a multistage pathway exclusively in the vagina and cervix of K14-HPV16 transgenic mice. Estrogen-induced carcinogenesis was accompanied by an incremental increase in the incidence and distribution of proliferating cells solely within the cervical and vaginal squamous epithelium of K14-HPV16 mice. Expression of the HPV transgenes in untreated transgenic mice was detectable only during estrus; estrogen treatment resulted in transgene expression that was persistent but not further upregulated, remaining at low levels at all stages of carcinogenesis. The data demonstrate a novel mechanism of synergistic cooperation between chronic estrogen exposure and the oncogenes of HPV16 that coordinates squamous carcinogenesis in the female reproductive tract of K14-HPV16 transgenic mice.

References

    1. Trends Microbiol. 1994 Jul;2(7):229-34
    1. Nat Genet. 1994 Feb;6(2):157-62
    1. Nature. 1986 Aug 14-20;322(6080):609-12
    1. Proc Natl Acad Sci U S A. 1985 Sep;82(18):6295-9
    1. Pharmacol Ther. 1990;47(2):203-18
    1. J Virol. 1994 Jul;68(7):4358-68
    1. Endocrinology. 1984 Mar;114(3):694-702
    1. Virology. 1991 Sep;184(1):9-13
    1. Int J Cancer. 1991 Sep 30;49(3):335-40
    1. Am J Pathol. 1989 Apr;134(4):733-9
    1. Prog Exp Tumor Res. 1960;1:179-224
    1. J Natl Cancer Inst. 1995 Jun 7;87(11):796-802
    1. Genes Dev. 1991 May;5(5):714-27
    1. Cancer Res. 1991 Dec 15;51(24):6493-505
    1. Carcinogenesis. 1993 Nov;14(11):2353-8
    1. Nature. 1986 Mar 13-19;320(6058):134-9
    1. Int J Cancer. 1987 Aug 15;40(2):198-201
    1. Int J Fertil Menopausal Stud. 1994;39 Suppl 2:99-114
    1. Genes Dev. 1990 Nov;4(11):1985-98
    1. Mol Cell Biol. 1982 Sep;2(9):1044-51
    1. Cancer Res. 1985 Feb;45(2):584-90
    1. Am J Epidemiol. 1994 Oct 15;140(8):700-10
    1. J Virol. 1993 Aug;67(8):4521-32
    1. Curr Top Microbiol Immunol. 1994;186:83-99
    1. Cancer Res. 1987 Jul 15;47(14):3886-8
    1. J Gen Virol. 1989 Aug;70 ( Pt 8):2227-32
    1. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2436-40
    1. Am J Obstet Gynecol. 1983 Jun 1;146(3):299-306
    1. Oncogene. 1995 Dec 21;11(12):2487-501
    1. Int J Cancer. 1991 Dec 2;49(6):867-9
    1. Genes Dev. 1994 Jun 1;8(11):1285-99
    1. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11162-6

Source: PubMed

3
Tilaa